吉非替尼与厄洛替尼治疗非小细胞肺癌的疗效观察

Efficacy of gefitinib and erlotinib in the treatment of non-small cell lung cancer

目的探讨吉非替尼与厄洛替尼治疗非小细胞肺癌(NSCLC)的临床疗效。方法选取2018年12月至2020年12月间建瓯市立医院收治的68例NSCLC患者,采用随机数字表法分为观察组和对照组,每组34例。对照组患者采用厄洛替尼治疗,观察组患者采用吉非替尼治疗,比较两组患者的临床疗效、细胞免疫功能及不良反应。结果观察组患者临床总有效率为55.9%,疾病控制率为79.4%,均高于对照组的35.3%和61.8%,差异均有统计学意义(均P<0.05)。治疗后,对照组患者CD3^(+)和CD4^(+)水平较治疗前下降(均P<0.05),观察组与治疗前比较,差异均无统计学意义(P>0.05);两组患者CD3^(+)和CD4^(+)水平比较,差异均有统计学意义(均P<0.05)。观察组患者不良反应发生率为14.7%,低于对照组的35.3%,差异有统计学意义(P<0.05)。结论与厄洛替尼相比,吉非替尼治疗NSCLC疗效更佳,安全性更高,可在临床推广应用。

Objective To investigate the clinical efficacy of gefitinib and erlotinib in the treatment of non-small cell lung cancer( NSCLC). Methods A total of 68 patients with NSCLC admitted to Jian’ou Municipal Hospital were selected from December 2018 to December 2020. They were divided into an observation group and a control group using random number table method with 34 patients in each group. The observation group was given gefitinib and the control group was given erlotinib. Clinical efficacy,cellular immune function and adverse reactions were compared between the two groups. Results The overall clinical efficacy rate was 55. 9% and disease control rate was 79. 4% in the observation group,which were significantly higher than 35. 3% and 61. 8%,respectively of the control group( all P<0.05). The levels of CD3^(+) and CD4^(+) were significantly reduced in the control group after treatment compared with before treatment( all P<0.05),but there was no significant difference in the levels of the above indicators in the observation group( P>0.05). The differences in the levels of the above indicators were statistically significant between the two groups( all P<0.05). The incidence of adverse reactions was 14. 7% in the observation group,which was significantly lower than 35. 3% of the control group( P<0.05). Conclusion Compared with erlotinib,gefitinib is effective and safe in the treatment of NSCLC and it should be promoted and applied in the clinical practice.